Oct 01, 2021 · Mass of uterus. Polycystic adnexal mass. Polycystic mass of uterine adnexa. Uterine mass. ICD-10-CM N85.8 is grouped within Diagnostic Related Group (s) (MS-DRG v39.0): 742 Uterine and adnexa procedures for non-malignancy with cc/mcc. 743 Uterine and adnexa procedures for non-malignancy without cc/mcc.
ICD-10-CM Diagnosis Code R22.1. Localized swelling, mass and lump, neck. 2016 2017 2018 2019 2020 2021 2022 Billable/Specific Code. ICD-10-CM Diagnosis Code C57.4 [convert to ICD-9-CM] Malignant neoplasm of uterine adnexa, unspecified. Cancer of the uterine adnexa; Primary malignant neoplasm of uterine adnexa.
Oct 01, 2021 · N85.2 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2022 edition of ICD-10-CM N85.2 became effective on October 1, 2021. This is the American ICD-10-CM version of N85.2 - other international versions of ICD-10 N85.2 may differ. Applicable To Bulky or enlarged uterus Type 1 Excludes
Oct 01, 2021 · 2022 ICD-10-CM Diagnosis Code D39.0 2022 ICD-10-CM Diagnosis Code D39.0 Neoplasm of uncertain behavior of uterus 2016 2017 2018 2019 2020 2021 2022 Billable/Specific Code D39.0 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes.
A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion'), unless the combination is specifically indexed elsewhere.
The 2022 edition of ICD-10-CM D39.0 became effective on October 1, 2021.
FY 2016 - New Code, effective from 10/1/2015 through 9/30/2016 (First year ICD-10-CM implemented into the HIPAA code set)
N85.8 is a billable diagnosis code used to specify a medical diagnosis of other specified noninflammatory disorders of uterus. The code N85.8 is valid during the fiscal year 2021 from October 01, 2020 through September 30, 2021 for the submission of HIPAA-covered transactions.
A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion'), unless the combination is specifically indexed elsewhere.
The 2022 edition of ICD-10-CM D25.1 became effective on October 1, 2021.
D39.0 is a billable diagnosis code used to specify a medical diagnosis of neoplasm of uncertain behavior of uterus. The code D39.0 is valid during the fiscal year 2021 from October 01, 2020 through September 30, 2021 for the submission of HIPAA-covered transactions.#N#The ICD-10-CM code D39.0 might also be used to specify conditions or terms like endometrial stromal tumor, intravenous leiomyomatosis, neoplasm of exocervix, neoplasm of isthmus of uterus, neoplasm of uncertain behavior of body of uterus , neoplasm of uncertain behavior of endocervix, etc.#N#The code D39.0 is applicable to female patients only. It is clinically and virtually impossible to use this code on a non-female patient.#N#The following anatomical sites found in the Table of Neoplasms apply to this code given the correct histological behavior: Neoplasm, neoplastic cervix (cervical) (uteri) (uterus) ; Neoplasm, neoplastic cervix (cervical) (uteri) (uterus) canal ; Neoplasm, neoplastic cervix (cervical) (uteri) (uterus) endocervix (canal) (gland) ; Neoplasm, neoplastic cervix (cervical) (uteri) (uterus) exocervix ; Neoplasm, neoplastic cervix (cervical) (uteri) (uterus) external os ; Neoplasm, neoplastic cervix (cervical) (uteri) (uterus) internal os ; Neoplasm, neoplastic cervix (cervical) (uteri) (uterus) nabothian gland ; etc
Causes can include hormones, thyroid problems, fibroids, polyps, cancer, infection, or pregnancy.